COMMUNIQUÉS West-GlobeNewswire

Pycnogenol® Offers Clinically Backed Cognitive Support Across Generations
23/09/2026
Research on French maritime pine bark extract spans children, students, working professionals and older adults looking to stay mentally sharp GENEVA, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Brain health is no longer a [...]
IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference
23/09/2026
ORLANDO, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it [...]
Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies
23/09/2026
SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced [...]
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
23/09/2026
SUNNYVALE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided [...]
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
23/09/2026
THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company [...]
NEXGEL Announces Dial-In Details for Investor Update Call
23/09/2026
LANGHORNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a company with a patient centric medical technology sales and marketing team working closely with clinicians [...]
Cheryl Polmatier Joins U.S. Oral Surgery Management as SVP of Payer Relations
23/09/2026
IRVING, Texas, Sept. 23, 2026 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management ( USOSM ) – a management services organization that exclusively serves premier oral and maxillofacial surgeons – has named Cheryl Polmatier [...]
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
23/09/2026
- Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders - REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that it has [...]
Scarlet Therapeutics Secures DARPA Agreement to Develop Adaptive Smart Red Blood Cells
23/09/2026
Agreement, worth up to $14 million, validates the potential of pioneering red blood cell technology platform BRISTOL, United Kingdom, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Scarlet Therapeutics Ltd (‘Scarlet’), a biotech [...]
Actimed Therapeutics Completes Recruitment for PROACT Phase 2a Study Evaluating S-pindolol benzoate (ACM 001.1) in Obese Adults During and After Semaglutide Therapy
23/09/2026
London, UK – 23 rd September 2026. Actimed Therapeutics Ltd (“Actimed”) has successfully completed patient recruitment for the PROACT Study (Protocol ACM 001 2024 01 CT; NCT07101939), a two part, Phase 2a, randomised, [...]
Engitix appoints Sonia Quaratino, MD, PhD as EVP Chief Medical Officer as its ECM pipeline moves toward clinical development
23/09/2026
LONDON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd., a biotechnology company pioneering extracellular matrix (ECM)-based discovery platforms to transform drug development in oncology, fibrosis and fibro‑inflammatory [...]
Boehringer Ingelheim and AWARE launch new Stop Rabies project in Zimbabwe to help protect dogs and communities
23/09/2026
Rabies remains one of the world’s deadliest yet preventable zoonotic diseases, highlighting the need for sustained prevention efforts. Through a new multi-year collaboration, Boehringer Ingelheim and AWARE are expanding [...]
Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer
23/09/2026
Veteran biotechnology executive, Daniel Passeri brings more than three decades of experience in oncology and immunotherapy drug development - Interim CEO Dr. Bo Rode Hansen resumes role as member of the Board of [...]
ITM and Lumara Bio Announce Upcoming Dosimetry and Re-treatment Data Presentations on ¹⁷⁷Lu-edotreotide at ASTRO 2026
23/09/2026
Garching / Munich, September 23 , 2026 — ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, and Lumara Bio , a dedicated oncology therapeutics division of ITM, today announced that [...]
La rage chez les otaries à fourrure du Cap : ce que les nouvelles recherches sud-africaines pourraient signifier pour le Canada
23/09/2026
OTTAWA, Ontario, 23 sept. 2026 (GLOBE NEWSWIRE) -- L’Institut canadien de santé animale (ICSA) est fier de perpétuer sa tradition annuelle consistant à organiser un webinaire éducatif à l’occasion de la Journée mondiale [...]
Rabies in Cape Fur Seals: What New South African Research Could Mean for Canada
23/09/2026
OTTAWA, Ontario, Sept. 23, 2026 (GLOBE NEWSWIRE) -- The Canadian Animal Health Institute (CAHI) is proud to continue its annual tradition of hosting an educational webinar in recognition of World Rabies Day. This year’s [...]
Change in Roche’s Board of Directors
23/09/2026
Roche announced today that the Board of Directors of Roche Holding Ltd has approved to propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roche’s Annual General [...]
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
23/09/2026
In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential Sefaxersen inhibits [...]
OSE Immunotherapeutics annonce la présentation des principaux résultats de l'étude de Phase 2 Combi-TED de Tedopi® dans le cancer du poumon non à petites cellules au Congrès 2026 de l’ESMO
23/09/2026
Nantes, France, 23 septembre 2026 – 7h30 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) , une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie [...]

Pages